contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-announces-the-next-generation-of-its-ce-ivd-marked-prostate-cancer-biopsy-ai-solution

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Johan Lundin talks about Aiforia’s journey from the start to today, at the University of Helsinki (I think), a week or two ago.  Nothing relevant from an investment perspective, but it was an interesting story overall, and provided many lessons and insights into how bumpy the early stages of building something like this are.

Here are Antti’s comments on Aiforia’s release of a new CE-IVD marked AI solution for prostate cancer diagnostics  Aiforia announced on Tuesday that it has released a new CE-IVD marked AI solution for prostate cancer diagnostics. The Aiforia® Prostate Cancer Biopsy solution is intended for the analysis of prostate samples. The news follows a similar recently announced tool for gastric cancer diagnostics. The launch of the new model supports our growth forecasts.                   Inderes              Aiforialle jälleen uusi CE-IVD-merkintä - Inderes    Uusi ratkaisu vahvistaa tuoteportfoliota ja tukee kasvuennustettamme.

Development time cut by more than half, customer deployment down to a few weeks. We expect accelerating growth, or in the words of NuWays, “hyperscale” years. From the transcript: Now we have this Vision Transformer technologies, Foundation Engine engines, all the nice things that we get from a latest technology. We think that we can reduce the development time from 18 months to 8 months. Significant, kind of a reduction on that. It’s a quicker to money on things when we decide to kind of build something and when we can actually commercialize it and, and change it as a revenue to our books. Customer deployment is another thing as well. Sometimes somebody has been questioning, how long time it will take that we deliver. If we look at the current situation, we’ve been using the latest technologies on kind of speeding up those processes, and we can actually deliver less than 4 weeks.

Aiforia’s development platform seems quite efficient, given how these approved algorithms are popping up like mushrooms after rain. Sure, ready-made classified samples are bought for different cancers, but this efficient??

Inderes              Aiforia julkistaa uuden sukupolven CE-IVD-merkityn tekoälyratkaisun...    Aiforia Technologies Oyj, Lehdistötiedote, 17.3.2026 klo 9.30Aiforia julkistaa uuden sukupolven CE-IVD-merkityn tekoälyratkaisun eturauhassyövän diagnostiikkaanAiforia Technologies Oyj julkisti...                             Amidst insider buying, an AI solution for prostate cancer diagnostics.

Is a campaign underway to signal “hey market, you’re delusional,” or a genuine nose for a good investment spot when the window to buy is briefly open after the earnings report?

More insider buys, 5,000 shares, Chief Product Officer: Aiforia Technologies Oyj – Johdon liiketoimet – Panu Kauppila - Inderes

Aiforia Technologies

Aiforia Technologies Plc, Press Release, March 17, 2026 at 9:30 a.m. EETAiforia announces the next generation of its CE-IVD marked Prostate Cancer Biopsy AI solution Aiforia Technologies Plc...

Aiforia Technologies Plc, Press Release, March 17, 2026 at 9:30 a.m. EETAiforia announces the next generation of its CE-IVD marked Prostate Cancer Biopsy AI solution&nbsp;Aiforia Technologies Plc today announced the launch of the next generation of its clinical AI solution for prostate cancer diagnostics. The&nbsp;Aiforia® Prostate Cancer Biopsy AI application is designed to enhance pathologists’ diagnostic workflow by providing world-class tools for comprehensive analysis and reporting of prostate needle biopsies. This solution is CE-IVD marked under the IVDR.This latest iteration of Aiforia’s AI solution for prostate cancer diagnostics is built on Aiforia’s Foundation Engine technology. Developed to perform robustly across real-world variation in sample quality, staining (including both H&amp;E and HES), and scanning, the innovative Foundation Engine provides a superior technological base that ensures consistent, high-quality performance. The AI solution integrates seamlessly into existing digital pathology workflows through the Aiforia® Clinical Suite Viewer, supporting full case review and reporting within a single user interface.“This release is a testament to Aiforia’s commitment to continuously bridging the gap between AI innovation and clinical practice. By leveraging our Foundation Engine, we ensure that the latest advancements in AI are perpetually integrated into the diagnostic frontline, providing pathologists with an ever-evolving toolkit to stay ahead of the most demanding clinical challenges. This release further strengthens Aiforia's broad portfolio of CE-IVD marked AI solutions,” says Jukka Tapaninen, CEO of Aiforia.Further inquiries Jukka Tapaninen, CEO, Aiforia Technologies Plc tel. +33 61 041 6686 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/ </a>Certified Adviser UB Corporate Finance Ltd ubcf@unitedbankers.fiAbout Aiforia Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.Find out more at <a href="http://aiforia.com/">www.aiforia.com</a>